Radionuclide therapy for osseous metastases in prostate cancer

Alain S. Abi-Ghanem, Mary A. McGrath, Heather A. Jacene

Research output: Contribution to journalArticle

Abstract

Bone metastases are associated with increased morbidity and poor prognosis in castration-resistant prostate cancer. Since 2010, 5 systemic therapies for metastatic castration-resistant prostate cancer have been approved by the US Food and Drug Administration based on an improvement in overall survival, offering alternatives to docetaxel, a chemotherapeutic agent with modest effect and significant toxicity. These systemic treatments belong to different classes of medication such as immunotherapy, hormonal therapy, chemotherapy, and radionuclide therapy. Radium-223 dichloride (223RaCl2), approved in May 2013, is a novel α-emitting radiopharmaceutical that targets areas of increased bone turnover in bone metastases, delivering densely ionizing radiation within a short tissue range and causing more severe chromosomal damage than β-emitting radiopharmaceuticals. In this article, we review the clinical development of 223RaCl2, focusing on its effects on pain relief, skeletal events, biochemical markers, overall survival, quality of life, and safety. We also outline the differences between 223RaCl2 and the previously developed bone-seeking β-emitters and briefly present new trials on the horizon involving 223RaCl2.

Original languageEnglish (US)
Pages (from-to)66-80
Number of pages15
JournalSeminars in Nuclear Medicine
Volume45
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Radioisotopes
Prostatic Neoplasms
Neoplasm Metastasis
Radiopharmaceuticals
Castration
docetaxel
Bone and Bones
Radium
Bone Remodeling
United States Food and Drug Administration
Therapeutics
Ionizing Radiation
Immunotherapy
Biomarkers
Quality of Life
Morbidity
Safety
Drug Therapy
Pain

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Radionuclide therapy for osseous metastases in prostate cancer. / Abi-Ghanem, Alain S.; McGrath, Mary A.; Jacene, Heather A.

In: Seminars in Nuclear Medicine, Vol. 45, No. 1, 01.01.2015, p. 66-80.

Research output: Contribution to journalArticle

Abi-Ghanem, Alain S. ; McGrath, Mary A. ; Jacene, Heather A. / Radionuclide therapy for osseous metastases in prostate cancer. In: Seminars in Nuclear Medicine. 2015 ; Vol. 45, No. 1. pp. 66-80.
@article{d2b77ad81c554e30a516f902588c5e94,
title = "Radionuclide therapy for osseous metastases in prostate cancer",
abstract = "Bone metastases are associated with increased morbidity and poor prognosis in castration-resistant prostate cancer. Since 2010, 5 systemic therapies for metastatic castration-resistant prostate cancer have been approved by the US Food and Drug Administration based on an improvement in overall survival, offering alternatives to docetaxel, a chemotherapeutic agent with modest effect and significant toxicity. These systemic treatments belong to different classes of medication such as immunotherapy, hormonal therapy, chemotherapy, and radionuclide therapy. Radium-223 dichloride (223RaCl2), approved in May 2013, is a novel α-emitting radiopharmaceutical that targets areas of increased bone turnover in bone metastases, delivering densely ionizing radiation within a short tissue range and causing more severe chromosomal damage than β-emitting radiopharmaceuticals. In this article, we review the clinical development of 223RaCl2, focusing on its effects on pain relief, skeletal events, biochemical markers, overall survival, quality of life, and safety. We also outline the differences between 223RaCl2 and the previously developed bone-seeking β-emitters and briefly present new trials on the horizon involving 223RaCl2.",
author = "Abi-Ghanem, {Alain S.} and McGrath, {Mary A.} and Jacene, {Heather A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1053/j.semnuclmed.2014.07.006",
language = "English (US)",
volume = "45",
pages = "66--80",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Radionuclide therapy for osseous metastases in prostate cancer

AU - Abi-Ghanem, Alain S.

AU - McGrath, Mary A.

AU - Jacene, Heather A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Bone metastases are associated with increased morbidity and poor prognosis in castration-resistant prostate cancer. Since 2010, 5 systemic therapies for metastatic castration-resistant prostate cancer have been approved by the US Food and Drug Administration based on an improvement in overall survival, offering alternatives to docetaxel, a chemotherapeutic agent with modest effect and significant toxicity. These systemic treatments belong to different classes of medication such as immunotherapy, hormonal therapy, chemotherapy, and radionuclide therapy. Radium-223 dichloride (223RaCl2), approved in May 2013, is a novel α-emitting radiopharmaceutical that targets areas of increased bone turnover in bone metastases, delivering densely ionizing radiation within a short tissue range and causing more severe chromosomal damage than β-emitting radiopharmaceuticals. In this article, we review the clinical development of 223RaCl2, focusing on its effects on pain relief, skeletal events, biochemical markers, overall survival, quality of life, and safety. We also outline the differences between 223RaCl2 and the previously developed bone-seeking β-emitters and briefly present new trials on the horizon involving 223RaCl2.

AB - Bone metastases are associated with increased morbidity and poor prognosis in castration-resistant prostate cancer. Since 2010, 5 systemic therapies for metastatic castration-resistant prostate cancer have been approved by the US Food and Drug Administration based on an improvement in overall survival, offering alternatives to docetaxel, a chemotherapeutic agent with modest effect and significant toxicity. These systemic treatments belong to different classes of medication such as immunotherapy, hormonal therapy, chemotherapy, and radionuclide therapy. Radium-223 dichloride (223RaCl2), approved in May 2013, is a novel α-emitting radiopharmaceutical that targets areas of increased bone turnover in bone metastases, delivering densely ionizing radiation within a short tissue range and causing more severe chromosomal damage than β-emitting radiopharmaceuticals. In this article, we review the clinical development of 223RaCl2, focusing on its effects on pain relief, skeletal events, biochemical markers, overall survival, quality of life, and safety. We also outline the differences between 223RaCl2 and the previously developed bone-seeking β-emitters and briefly present new trials on the horizon involving 223RaCl2.

UR - http://www.scopus.com/inward/record.url?scp=84919432477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919432477&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2014.07.006

DO - 10.1053/j.semnuclmed.2014.07.006

M3 - Article

C2 - 25475380

AN - SCOPUS:84919432477

VL - 45

SP - 66

EP - 80

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 1

ER -